Poxel SA
7PO
Company Profile
Business description
Poxel SA is a biopharmaceutical company. It is focused on the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as nonalcoholic steatohepatitis (NASH) and rare disorders (ALD/AMN). It has developed a portfolio of drug candidates, including its candidates: Imeglimin, for the treatment of type 2 diabetes, and PXL770 and PXL065, for the treatment of NASH.
Contact
259/261 Avenue Jean Jaures
Immeuble le Sunway
Lyon69007
FRAT: +33 437372010
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
5
Stocks News & Analysis
stocks
Market pricing in further upside in overvalued ASX bank
We view the shares are materially overvalued.
stocks
Chart of the Week: Lithium is rebounding on rising demand
The mining sector is significantly overvalued on average but select value to be found.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,238.70 | 21.50 | 0.23% |
| CAC 40 | 8,429.03 | 0.00 | 0.00% |
| DAX 40 | 25,278.21 | 279.81 | 1.12% |
| Dow JONES (US) | 49,549.64 | 16.45 | 0.03% |
| FTSE 100 | 10,686.18 | 130.01 | 1.23% |
| HKSE | 26,705.94 | 138.82 | 0.52% |
| NASDAQ | 22,677.99 | 99.61 | 0.44% |
| Nikkei 225 | 57,143.84 | 577.35 | 1.02% |
| NZX 50 Index | 13,247.02 | 129.11 | 0.98% |
| S&P 500 | 6,860.77 | 17.55 | 0.26% |
| S&P/ASX 200 | 9,007.00 | 12.80 | 0.14% |
| SSE Composite Index | 4,082.07 | 51.95 | -1.26% |